- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06746753
Système rénine-angiotensine dysfonctionnel en cas de choc septique (MANTRA)
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will determine whether normalization of renin-angiotensin-aldosterone system (RAAS) signaling in sepsis occurs more rapidly with treatment with Angiotensin II compared with conventional vasopressors. Trial samples will be used to identify the best RAAS biomarker predictor of treatment response via in-depth longitudinal analysis of RAAS component and to determine the extent and mechanisms of Angiotensin II impact on innate immune function during sepsis. Successful accomplishment of our aims will provide the capability to improve endotyping of septic patients by establishing the most precise and robust measurement of renin (and RAAS dysfunction). This work will improve staging and clinical precision and will facilitate the criteria for therapeutic development of targets in septic shock.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ashish Khanna, MD
- Numéro de téléphone: 513-658-5866
- E-mail: ashish.khanna@wfusm.edu
Sauvegarde des contacts de l'étude
- Nom: Lynnette Harris, RN
- Numéro de téléphone: 336-716-8791
- E-mail: lynnette.harris@advocatehealth.org
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital-Harvard
-
Contact:
- Michael R Filbin, MD, MS
- E-mail: mfilbin@mgh.harvard.edu
-
Contact:
- Daniel E Leisman, MD
- E-mail: dleisman@mgh.harvard.edu
-
Chercheur principal:
- Michael R Filbin, MD, MS
-
Chercheur principal:
- Daniel E Leisman, MD
-
Sous-enquêteur:
- Marcia Goldberg, MD
-
Sous-enquêteur:
- Kathryn Hibbert, MD
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27157
- Atrium Health Wake Forest Baptist
-
Contact:
- Lynnette C Harris, BSN
- Numéro de téléphone: 336-716-8791
- E-mail: lcharris@wakehealth.edu
-
Contact:
- Ashish Khanna, MD
- Numéro de téléphone: 513-658-5866
- E-mail: akhanna@wakehealth.edu
-
Chercheur principal:
- Ashish Khanna, MD
-
Sous-enquêteur:
- Christopher Schaich, PhD
-
Sous-enquêteur:
- Daniel C Files, MD
-
Chercheur principal:
- Mark Chappell, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival
Exclusion Criteria:
- Age <18 years
- Prisoners
- Pregnant women
- Patients for whom urgent surgery is anticipated
- Leukocyte count <1,000 cells/μL
- Absolute monocyte count <200 cells/μL
- Bone marrow transplant within the past 30 days
- Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
- transfer from outside ICU
- history of liver cirrhosis with Child-Pugh score ≥6
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Angiotensin II
Continuous infusion of Angiotensin II for up to 48 hours |
randomized to receive Angiotensin II continuous infusion for up to 48 hours |
|
Comparateur actif: Norepinephrine
Continuous infusion of Norepinephrine for up to 48 hours |
randomized to receive Norepinephrine continuous infusion for up to 48 hours |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean Renin Level - Hour 24
Délai: Hour 24
|
Mean plasma renin level (PRA) as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Hour 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Norepinephrine Equivalent Dose Requirement (NEE)
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
NEE indicates severity of shock and need for vasopressors to support blood pressure. Normal range is 0.0-1.0 mcg/kg/min. Levels above normal indicate shock and need for vasopressors. The higher the level the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Number of Days Without Renal Replacement Therapy
Délai: Day 28
|
Number of days without renal replacement therapy |
Day 28
|
|
Number of Days of Vasopressor Use
Délai: Day 28
|
Number of days without vasopressor use |
Day 28
|
|
Number of Days Without Mechanical Ventilation
Délai: Day 28
|
Number of days without invasive mechanical ventilation |
Day 28
|
|
Number of Hours Vasopressor Free
Délai: Hour 72
|
Number of hours without requiring vasopressors during first 72 hours after randomization |
Hour 72
|
|
Number of Hours Alive
Délai: Hour 72
|
Number of hours alive during first 72 hours after randomization |
Hour 72
|
|
Number of Days Alive
Délai: Day 28
|
Number of days alive |
Day 28
|
|
Mean Renin Level
Délai: Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
Mean renin level as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
|
Sequential Organ Failure Assessment (SOFA) Score
Délai: Baseline, Hour 24, Hour 48
|
SOFA score indicates the number and severity of failed organs and provides prognostic information on in-hospital survival in patients with severe sepsis and septic shock. Score above 0 indicates organ failure. The higher the score the more failed organs and degree of organ failure. |
Baseline, Hour 24, Hour 48
|
|
APACHE-II Score
Délai: Baseline, Hour 24, Hour 48
|
APACHE-II score assesses severity of illness in critically ill patients and indicates risk of mortality. Score range 0-10 low risk of mortality, 11-20 moderate risk, 21-30 high risk, 31 or above very high risk. |
Baseline, Hour 24, Hour 48
|
|
Lactate Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Lactate is an indicator of sepsis severity. Levels 2.3-20 mmol/L indicate sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Kidney Disease Improving Global Outcomes (KDIGO) Stage
Délai: Baseline, Hour 24, Hour 48
|
Participant stage of acute kidney injury will be determined as follows Stage 1: Increase in serum creatinine ≥ 0.3 mg/dL in 48 hours or 1.5 to 1.9 multiplied by baseline (in 7 days); Stage 2: 2.0 to 2.9 multiplied by baseline serum creatinine; Stage 3: 3.0 or more multiplied by baseline; increase in serum creatinine ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage. Higher stage indicates higher severity of renal failure. |
Baseline, Hour 24, Hour 48
|
|
Creatinine Level
Délai: Baseline, Hour 24, Hour 48
|
Creatinine level is an indicator of renal disease severity. Normal range for women 0.7-1.3 mg/dL, men 0.6-1.1 mg/dL. Levels higher than normal indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
BUN Level
Délai: Baseline, Hour 24, Hour 48
|
BUN level is an indicator of renal disease severity. Levels above 24 mg/dL indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bicarbonate Level
Délai: Baseline, Hour 24, Hour 48
|
Bicarbonate level is an indicator of acid base disturbance severity. Normal range is 22-29 mEq/L. Levels above or below the normal range indicate acid base disturbance. The higher the score the more severe. |
Baseline, Hour 24, Hour 48
|
|
Number of Participants with Acute Respiratory Distress Syndrome (ARDS)
Délai: Baseline, Hour 24, Hour 48
|
Number of participants with ARDS |
Baseline, Hour 24, Hour 48
|
|
SpO2/FiO2 Ratio Level
Délai: Baseline, Hour 24, Hour 48
|
SpO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 315-235, moderate severity 148-235, severe <148. |
Baseline, Hour 24, Hour 48
|
|
PaO2/FiO2 Ratio Level
Délai: Baseline, Hour 24, Hour 48
|
PaO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 201-300 mmHg; moderate severity 101-200 mmHg, severe ≤ 100 mmHg. |
Baseline, Hour 24, Hour 48
|
|
Serum Aspartate Aminotransferases Level
Délai: Baseline, Hour 24, Hour 48
|
Serum aspartate aminotransferases level is an indicator of liver injury severity. Normal range 8-48 U/L. Levels above normal indicate livery injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alanine Aminotransferases Level
Délai: Baseline, Hour 24, Hour 48
|
Alanine aminotransferases level is indicator of liver injury severity. Normal range 7-55 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alkaline Phosphatase Level
Délai: Baseline, Hour 24, Hour 48
|
Alkaline phosphatase level is an indicator of liver injury severity. Normal range 40-129 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bilirubin Level
Délai: Baseline, Hour 24, Hour 48
|
Bilirubin level is an indicator of liver injury severity. Normal range 0.1-1.2 mg/dL. Levels higher than normal indicate liver injury. The higher the liver the more severe. |
Baseline, Hour 24, Hour 48
|
|
Albumin Level
Délai: Baseline, Hour 24, Hour 48
|
Albumin level is an indicator of liver injury severity. Normal range 3.5-5.0 g/dL. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin I Level
Délai: Baseline, Hour 24, Hour 48
|
Troponin I level is an indicator of cardiac myocyte injury. Normal range 0-0.04 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin T Level
Délai: Baseline, Hour 24, Hour 48
|
Troponin T level is an indicator of cardiac myocyte injury. Normal range 0-0.01 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Serum Level
Délai: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin serum level indicates risk of kidney injury. Normal serum level is <10 mcg/L. Levels higher than normal indicate risk of kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Urine Level
Délai: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin urine level indicates risk of kidney injury. Normal urine level is ≤50 ng/ml. Risk of kidney disease: Low risk 51-149 ng/ml, moderate risk 150-299 ng/ml, and high risk ≥300 ng/ml. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Urine Level
Délai: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I urine level is used to detect kidney injury. Normal level is <1 ng/ml. Levels higher than normal indicate ischemic kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Blood Level
Délai: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I blood level is used to detect kidney injury. Normal levels 0.42-2.0 ng/ml. Levels higher than normal indicate kidney injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Soluble Receptor for Advanced Glycation End Product Level
Délai: Baseline, Hour 24, Hour 48
|
Soluble receptor for advanced glycation end product level is a marker of aging, hypertension and diabetes. Normal range is 647-1248 pg/ml. Levels higher than normal indicate risk for hypertension and diabetes. |
Baseline, Hour 24, Hour 48
|
|
Angiopoietin-2 Level
Délai: Baseline, Hour 24, Hour 48, Hour 72
|
Angiopoietin-2 level is a marker of inflammation. Normal range is 1434-4141 pg/mL. Levels higher than normal indicate inflammation. |
Baseline, Hour 24, Hour 48, Hour 72
|
|
Syndecan-1 Level
Délai: Baseline, Hour 24, Hour 48
|
Syndecan-1 level is a marker of disease severity in critically ill patients. Levels >20ng/ml indicate severe disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Protein C Level
Délai: Baseline, Hour 24, Hour 48
|
Protein C level is an indicator of inflammation and thrombotic state. Normal level is <8 mg/L. Levels higher than normal indicate inflammation and thrombotic state. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neuron-Specific Enolase Level
Délai: Baseline, Hour 24, Hour 48
|
Neuron-specific enolase level is an indicator of brain injury. Normal range is 16-17 ug/L. Levels higher than normal indicate brain injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
S-100β Level
Délai: Baseline, Hour 24, Hour 48
|
S-100β level is indicator of brain injury. Normal range is 0.02-0.05 μg/dL. Levels higher than normal indicate brain injury. The higher the number the more severe. |
Baseline, Hour 24, Hour 48
|
|
TNFα Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
TNFα level is an indicator of systemic inflammation. Normal levels are 75 +/- 15 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sTNFR1 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sTNFR1 level is an indicator of systemic inflammation. Normal levels are <2.4 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-6 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-6 level is an indicator of systemic inflammation. Normal range is 0-43.5 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sIL-6R Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sIL-6R level is an indicator of systemic inflammation. Normal range is 14-46 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-8 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-8 level is an indicator of systemic inflammation. Normal range is 0-66.1 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1β Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1β level is an indicator of systemic inflammation. Normal range is 0.5-12 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Interferon Gamma Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IFN-ɣ level is an indicator of systemic inflammation. Normal range is 0-8.6 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL12p70 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL12p70 level is an indicator of systemic inflammation. Normal range is 0-1.9 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-17 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-17 level is an indicator of systemic inflammation. Normal range is 0-1.4 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-alpha Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-αlpha level is an indicator of systemic inflammation. Normal range is 0-208 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-beta Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-beta level is an indicator of systemic inflammation. Normal range is 59-647 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IP-10 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IP-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-10 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1RA Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1RA level is an indicator of systemic inflammation. Normal range is 100-300 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-12p40 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-12p40 level is an indicator of systemic inflammation. Normal range is 0.064-1000 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
C reactive protein (CRP) Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
CRP level is an indicator of systemic inflammation. Normal range is 0-10 mg/dl. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Procalcitonin Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Procalcitonin level is an indicator of systemic inflammation. Levels >0.25 mg/ml indicate inflammation and infection. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Platelet Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Platelet level is an indicator of systemic inflammation and thrombocytosis. Normal range is 150000-450000 platelets per microliter. Levels higher than normal indicate inflammation and thrombocytosis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Neutrophil Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute neutrophil count level is an indicator of inflammation and infection/sepsis. Normal range is 2500-7000 neutrophils per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Granulocyte Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute granulocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1500-8500 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Lymphocytes Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute lymphocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1000-4800 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Neutrophil-Lymphocyte Ratio Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Neutrophil-lymphocyte ratio level is an indicator of inflammation and infection/sepsis or marrow malignancy. Normal range is 1-2. Levels higher than normal indicate inflammation, infection/sepsis, marrow malignancy. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Angiotensin (1-7)
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Angiotensin (1-7) level as a measure of the renin-angiotensin-aldosterone system |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Plasma renin activity
Délai: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Prorenin
Délai: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Soluble prorenin receptor (sPRR)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Aldosterone
Délai: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Intact Aogen
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
ANG II
Délai: baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
|
Angiotensin-converting enzyme (ACE)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Angiotensin-converting enzyme-2 (ACE2)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Dipeptidyl peptidase 3 (DPP3)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
RNA Paxgene Bulk (Bulk RNA sequencing)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Whole blood cryopreserved (scRNAsesq)
Délai: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patients with New Deep Venous Thrombosis
Délai: Day 7, Day 28
|
Number of patients with development of new deep venous thrombosis |
Day 7, Day 28
|
|
Patients with New Pulmonary Embolism
Délai: Day 7, Day 28
|
Number of patients with development of new pulmonary embolism |
Day 7, Day 28
|
|
Patients with New-Onset Atrial Fibrillation
Délai: Hour 72, day 28
|
Number of patients with new-onset atrial fibrillation |
Hour 72, day 28
|
|
Patients with New-Onset Ventricular Arrhythmias
Délai: Hour 72, Day 7, Day 28
|
Number of patients with new-onset ventricular arrhythmias |
Hour 72, Day 7, Day 28
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ashish Khanna, MD, Atrium Health Wake Forest Baptist
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Infections
- Syndrome de réponse inflammatoire systémique
- Inflammation
- Choc
- Conditions pathologiques, signes et symptômes
- État septique
- Maladies rénales
- Choc, Septique
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Hormones peptidiques
- Neuropeptides
- Peptides
- Acides aminés, peptides et protéines
- Oligopeptides
- Protéines de tissu nerveux
- Protéines
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Facteurs biologiques
- Hydrocarbures, aromatique
- Amines
- Catéchols
- Phénols
- Dérivés de benzène
- Alcools
- Alcools amino
- Éthanolamines
- Autacoïdes
- Médiateurs d'inflammation
- Monoamines biogéniques
- Amines biogéniques
- Catécholamines
- Angiotensines
- Norépinéphrine
- Angiotensine II
Autres numéros d'identification d'étude
- IRB00115287
- R01HL177834 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .